BMPR2 and pulmonary arterial hypertension: In 2016, other investigators used intravenous injection of Ad-mediated endothelial Bmpr2 gene therapy to reverse PAH in mice carrying a Bmpr2 mutation, as shown by reduced right ventricle systolic pressure and hypertrophy.